---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-012133"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:13:31.711920+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Protalix Q2 2024: revenue $13.5M, net loss $2.2M; PRX-115 Phase I topline expected Q3

## Summary
- Total Q2 2024 revenue $13.5M vs $35.1M in Q2 2023; net loss $2.2M ($0.03/sh) vs net income $19.3M ($0.29/sh).
- Product revenue from goods $13.3M (-12% YoY); license & R&D revenue $0.2M (vs $20.0M milestone from Chiesi in Q2 2023).
- PRX-115 (uncontrolled gout) Phase I: positive topline from first 7 cohorts; 8th cohort dosed, full results expected Q3 2024.
- Cash, cash equivalents and short-term bank deposits $45.0M at June 30, 2024; post-quarter collected $4.6M from Pfizer, $2.3M from Brazil.
- R&D expenses decreased 33% to $3.0M due to completion of Fabry clinical program and Elfabrio regulatory processes.

## SEC filing metadata
- accession: 0001558370-24-012133
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837024012133/0001558370-24-012133-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837024012133/plx-20240814x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-012133
- JSON: https://secwatch.observer/filing/0001558370-24-012133.json
- Plain text: https://secwatch.observer/filing/0001558370-24-012133.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.